502 related articles for article (PubMed ID: 18055849)
1. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
3. Glucarpidase following high-dose methotrexate: update on development.
Patterson DM; Lee SM
Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
[TBL] [Abstract][Full Text] [Related]
4. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
5. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
6. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
7. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
8. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
9. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
10. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
Tuffaha HW; Al Omar S
J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
[TBL] [Abstract][Full Text] [Related]
11. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
12. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
[TBL] [Abstract][Full Text] [Related]
14. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
15. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
17. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
18. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
20. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
